An Official Website of the United States Government
Company Information:
Name:
CHANTEST, INC.
Address:
14656 NEO PKY
CLEVELAND, OH 44128-
CLEVELAND, OH 44128-
Located in HUBZone:
No
Woman-Owned:
Yes
Minority-Owned:
No
URL:
N/A
Phone:
(216) 332-1665
Award Totals:
Award List:
NOVEL SIMPLE SCREEN FOR POTASSIUM CHANNELS
Award Year / Program / Phase:
1998 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Lacerda, Antonio E
Award Amount:
$89,263.00
New drugs for treatment of atrial fibrillation
Award Year / Program / Phase:
2001 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Award Amount:
$99,924.00
Abstract:
Atrial fibrillation (AF) is the commonest cardiac arrhythmia and in its chronic form affects more than two million patients in the USA. AF is associated with cardiac and non-cardiac diseases. About 10% of cases have no obvious cause (lone AF). Stroke is the commonest complication with a 25% greater… More
New drugs for treatment of atrial fibrillation
Award Year / Program / Phase:
2003 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Award Amount:
$0.00
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More
New drugs for treatment of atrial fibrillation
Award Year / Program / Phase:
2003 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Antonio E. Lacerda
Award Amount:
$580,448.00
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cause of arrhythmias in the elderly; it has an incidence of more than 5 percent in people > 69 years of age. At present, there is no satisfactory treatment of this disease. The ChanTest Phase I SBIR was directed towards… More
Development of a Complete Proarrhythmic Safety Profile for Drugs
Award Year / Program / Phase:
2006 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
James W. Kramer
Award Amount:
$149,322.00
Abstract:
DESCRIPTION (provided by applicant): ChanTest's goal is to commercialize a comprehensive non-clinical proarrhythmic profile that will screen compounds through a battery of models that span from the molecular (ion channels) to the multicellular (Purkinje fibers) to whole organ (Langendorff perfused… More
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Andrew H. Brueningwright
Award Amount:
$149,275.00
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre-clinical cardiac safety screening. We have recently characterized a population of SC-hCMs that will be made commer
cially available in 2010 by our… More
Optimizing the Action Potential of Stem Cell-derived Human Cardiomyocytes for Car
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Andrew H. Bruening-wright – 503-494-7732
Award Amount:
$1,184,308.00
Abstract:
DESCRIPTION (provided by applicant): Stem Cell-derived Human Cardiomyocytes (SC-hCMs) offer great potential for improving the accuracy of pre- clinical cardiac safety testing. We have characterized a population of SC-hCMs and have demonstrated that these cells show sensitive pharmacology that… More